|Bid||114.100 x 400|
|Ask||114.370 x 100|
|Day's Range||96.340 - 116.932|
|52 Week Range||31.380 - 116.932|
|PE Ratio (TTM)||-22.18|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Alnylam Pharmaceuticals Inc's RNAi-based drug that targets a rare genetic disease met the main goal of a key study, in a breakthrough for the new class of medicines that works by blocking disease-causing proteins. Alnylam's patisiran belongs to a class of drugs that uses the Nobel-prize winning RNA interference (RNAi) mechanism to manipulate ribonucleic acid, which interferes with or "silences" targeted genes, and stops the formation of proteins that can cause diseases.
Phase 3 trials of Alnylam's patisiran were a success, paving the way to an FDA filing for approval later this year.
One biotech's phase 3 success means competition for the other.